Literature DB >> 18829552

ATM and the Mre11-Rad50-Nbs1 complex respond to nucleoside analogue-induced stalled replication forks and contribute to drug resistance.

Brett Ewald1, Deepa Sampath, William Plunkett.   

Abstract

The Mre11-Rad50-Nbs1 complex and autophosphorylated Ser(1981)-ATM are involved in recognizing and repairing DNA damage, such as double-strand breaks (DSB). However, the role of these factors in response to stalled replication forks is not clear. Nucleoside analogues are agents that are incorporated into DNA during replication, which cause stalling of replication forks. The molecular mechanisms that sense these events may signal for DNA repair and contribute to survival but are poorly understood. Cellular responses to both DSBs and stalled replication forks are marked by H2AX phosphorylation on Ser(139) (gamma-H2AX), which forms nuclear foci at sites of DNA damage. Here, concentrations of the nucleoside analogues 1-beta-d-arabinofuranosylcytosine (cytarabine; ara-C), gemcitabine, and troxacitabine, which inhibited DNA synthesis by 90% within 2 hours, were determined for each agent. Using gamma-H2AX as a marker for changes in chromatin structure, we show that Mre11, Rad50, Nbs1, and phosphorylated ATM respond to nucleoside analogue-induced stalled replication forks by forming nuclear foci that colocalize with gamma-H2AX within 2 hours. Because neither DSBs nor single-strand breaks were detectable after nucleoside analogue exposure, we conclude that this molecular response is not due to the presence of DNA breaks. Deficiencies in ATM, Mre11, or Rad50 led to a 2- to 5-fold increase in clonogenic sensitization to gemcitabine, whereas Nbs1 and H2AX deficiency did not affect reproductive growth. Taken together, these results suggest that ATM, Mre11, and Rad50 are required for survival after replication fork stalling, whereas Nbs1 and H2AX are inconsequential.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18829552      PMCID: PMC2631429          DOI: 10.1158/0008-5472.CAN-08-0971

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  50 in total

Review 1.  Heterogeneity of eukaryotic replicons, replicon clusters, and replication foci.

Authors:  R Berezney; D D Dubey; J A Huberman
Journal:  Chromosoma       Date:  2000-03       Impact factor: 4.316

2.  DNA damage-dependent nuclear dynamics of the Mre11 complex.

Authors:  O K Mirzoeva; J H Petrini
Journal:  Mol Cell Biol       Date:  2001-01       Impact factor: 4.272

3.  S-Phase arrest by nucleoside analogues and abrogation of survival without cell cycle progression by 7-hydroxystaurosporine.

Authors:  Z Shi; A Azuma; D Sampath; Y X Li; P Huang; W Plunkett
Journal:  Cancer Res       Date:  2001-02-01       Impact factor: 12.701

4.  The forkhead-associated domain of NBS1 is essential for nuclear foci formation after irradiation but not essential for hRAD50[middle dot]hMRE11[middle dot]NBS1 complex DNA repair activity.

Authors:  H Tauchi; J Kobayashi; K Morishima; S Matsuura; A Nakamura; T Shiraishi; E Ito; D Masnada; D Delia; K Komatsu
Journal:  J Biol Chem       Date:  2001-01-05       Impact factor: 5.157

5.  Mre11 complex and DNA replication: linkage to E2F and sites of DNA synthesis.

Authors:  R S Maser; O K Mirzoeva; J Wells; H Olivares; B R Williams; R A Zinkel; P J Farnham; J H Petrini
Journal:  Mol Cell Biol       Date:  2001-09       Impact factor: 4.272

6.  Mre11 protein complex prevents double-strand break accumulation during chromosomal DNA replication.

Authors:  V Costanzo; K Robertson; M Bibikova; E Kim; D Grieco; M Gottesman; D Carroll; J Gautier
Journal:  Mol Cell       Date:  2001-07       Impact factor: 17.970

7.  The DNA double-strand break repair gene hMRE11 is mutated in individuals with an ataxia-telangiectasia-like disorder.

Authors:  G S Stewart; R S Maser; T Stankovic; D A Bressan; M I Kaplan; N G Jaspers; A Raams; P J Byrd; J H Petrini; A M Taylor
Journal:  Cell       Date:  1999-12-10       Impact factor: 41.582

8.  A novel action of human apurinic/apyrimidinic endonuclease: excision of L-configuration deoxyribonucleoside analogs from the 3' termini of DNA.

Authors:  K M Chou; M Kukhanova; Y C Cheng
Journal:  J Biol Chem       Date:  2000-10-06       Impact factor: 5.157

9.  Hyperthermia activates a subset of ataxia-telangiectasia mutated effectors independent of DNA strand breaks and heat shock protein 70 status.

Authors:  Clayton R Hunt; Raj K Pandita; Andrei Laszlo; Ryuji Higashikubo; Manjula Agarwal; Tetsuya Kitamura; Arun Gupta; Nicole Rief; Nobuo Horikoshi; Rajeskaran Baskaran; Ji-Hoon Lee; Markus Löbrich; Tanya T Paull; Joseph L Roti Roti; Tej K Pandita
Journal:  Cancer Res       Date:  2007-04-01       Impact factor: 12.701

10.  Dynamics of DNA replication factories in living cells.

Authors:  H Leonhardt; H P Rahn; P Weinzierl; A Sporbert; T Cremer; D Zink; M C Cardoso
Journal:  J Cell Biol       Date:  2000-04-17       Impact factor: 10.539

View more
  19 in total

1.  The human immunodeficiency virus protease inhibitor ritonavir inhibits lung cancer cells, in part, by inhibition of survivin.

Authors:  Anjaiah Srirangam; Monica Milani; Ranjana Mitra; Zhijun Guo; Mariangellys Rodriguez; Hitesh Kathuria; Seiji Fukuda; Anthony Rizzardi; Stephen Schmechel; David G Skalnik; Louis M Pelus; David A Potter
Journal:  J Thorac Oncol       Date:  2011-04       Impact factor: 15.609

2.  Homologous recombination as a resistance mechanism to replication-induced double-strand breaks caused by the antileukemia agent CNDAC.

Authors:  Xiaojun Liu; Yaqing Wang; Sherri Benaissa; Akira Matsuda; Hagop Kantarjian; Zeev Estrov; William Plunkett
Journal:  Blood       Date:  2010-05-17       Impact factor: 22.113

3.  Hyperthermia inhibits recombination repair of gemcitabine-stalled replication forks.

Authors:  Mustafa Raoof; Cihui Zhu; Brandon T Cisneros; Heping Liu; Stuart J Corr; Lon J Wilson; Steven A Curley
Journal:  J Natl Cancer Inst       Date:  2014-08-15       Impact factor: 13.506

4.  Plk1 inhibition enhances the efficacy of gemcitabine in human pancreatic cancer.

Authors:  Jie Li; Ruixin Wang; Patrick G Schweickert; Anju Karki; Yi Yang; Yifan Kong; Nihal Ahmad; Stephen F Konieczny; Xiaoqi Liu
Journal:  Cell Cycle       Date:  2016       Impact factor: 4.534

5.  Requirement for NBS1 in the S phase checkpoint response to DNA methylation combined with PARP inhibition.

Authors:  Julie K Horton; Donna F Stefanick; Jennifer Y Zeng; Michael J Carrozza; Samuel H Wilson
Journal:  DNA Repair (Amst)       Date:  2010-12-03

6.  Phase I and pharmacologic trial of cytosine arabinoside with the selective checkpoint 1 inhibitor Sch 900776 in refractory acute leukemias.

Authors:  Judith E Karp; Brian M Thomas; Jacqueline M Greer; Christopher Sorge; Steven D Gore; Keith W Pratz; B Douglas Smith; Karen S Flatten; Kevin Peterson; Paula Schneider; Karen Mackey; Tomoko Freshwater; Mark J Levis; Michael A McDevitt; Hetty E Carraway; Douglas E Gladstone; Margaret M Showel; Sabine Loechner; David A Parry; Jo Ann Horowitz; Randi Isaacs; Scott H Kaufmann
Journal:  Clin Cancer Res       Date:  2012-10-23       Impact factor: 12.531

7.  Superresolution imaging of individual replication forks reveals unexpected prodrug resistance mechanism.

Authors:  Therese Triemer; Alessandra Messikommer; Stella M K Glasauer; Jawad Alzeer; Miriam H Paulisch; Nathan W Luedtke
Journal:  Proc Natl Acad Sci U S A       Date:  2018-01-29       Impact factor: 11.205

Review 8.  Plk1 Inhibitors in Cancer Therapy: From Laboratory to Clinics.

Authors:  Rosie Elizabeth Ann Gutteridge; Mary Ann Ndiaye; Xiaoqi Liu; Nihal Ahmad
Journal:  Mol Cancer Ther       Date:  2016-06-21       Impact factor: 6.261

Review 9.  Ovarian cancer: in search of better marker systems based on DNA repair defects.

Authors:  Dominic Varga; Miriam Deniz; Lukas Schwentner; Lisa Wiesmüller
Journal:  Int J Mol Sci       Date:  2013-01-04       Impact factor: 5.923

10.  Gemcitabine induces poly (ADP-ribose) polymerase-1 (PARP-1) degradation through autophagy in pancreatic cancer.

Authors:  Yufeng Wang; Yasuhiro Kuramitsu; Kazuhiro Tokuda; Byron Baron; Takao Kitagawa; Junko Akada; Shin-ichiro Maehara; Yoshihiko Maehara; Kazuyuki Nakamura
Journal:  PLoS One       Date:  2014-10-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.